title: Coronary stenting in stable patients: identification of a low-risk subgroup that may not require adjunctive antiplatelet therapy.
abstract: The present study prospectively evaluated adjunctive antiplatelet therapy in patients without insulin-requiring diabetes during elective coronary stenting. Three hundred patients were randomized to one of three treatment groups: clopidogrel pretreatment, adjunctive abciximab, or control. Stenting was successful in 98% and no deaths occurred. Thirty-day and 1-year major adverse coronary events (MACEs) was similar in all groups. A subgroup of 109 patients undergoing single-vessel stenting of type A/B1 lesions with short guidewire times had no postprocedure myocardial infarction or 30-day MACE. We conclude that patients with these characteristics may safely undergo elective coronary stenting without adjunctive antiplatelet therapy.
authors.affiliation: Wake Heart Center, Raleigh, North Carolina 27610, USA. wakeheartresearch@msn.com
authors.forename: Tift
authors.initials: T
authors.lastname: Mann
authors.forename: Roberto J
authors.initials: RJ
authors.lastname: Cubeddu
authors.forename: Laura
authors.initials: L
authors.lastname: Raynor
authors.forename: Josie
authors.initials: J
authors.lastname: Bowen
authors.forename: Joel E
authors.initials: JE
authors.lastname: Schneider
authors.forename: Gregory
authors.initials: G
authors.lastname: Rose
authors.forename: Gabriela
authors.initials: G
authors.lastname: Cubeddu
authors.forename: Jaffar Ali
authors.initials: JA
authors.lastname: Raza
authors.forename: Robert Lee
authors.initials: RL
authors.lastname: Jobe
authors.forename: William
authors.initials: W
authors.lastname: Newman
authors.forename: Micheal
authors.initials: M
authors.lastname: Zellinger
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000175:diagnosis; D003925:Diabetic Angiopathies / Q000150:complications / Q000175:diagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D008297:Male; D011336:Probability; D011446:Prospective Studies; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D015607:Stents; D016019:Survival Analysis; D013988:Ticlopidine / Q000008:administration & dosage* / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D000077144:Clopidogrel; D013988:Ticlopidine; D000077284:Abciximab